HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail TherapeuticsNEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”, the “Company”) today announced the completion of the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. (“NeoTrail”). The purchase price remains undisclosed. The asset purchase agreement ...